Acorda Therapeutics, Inc. (NASDAQ:ACOR) shares are trading at around $36 and generated a 16% return last year. They have the potential to deliver around a 50% return this year.
The following reasons could be cited as the potential drivers of the stock.
1. The company, like every year increased the price of its drug Ampyra by 10.75%, effective from January 2014. This price hike is consistent with the company's strategy, as it has been raising the price of Amprya in the first quarter every year. The drug improves walking in patients suffering from Multiple sclerosis (NYSE:MS). In the recently released fourth-quarter results, the drug reported revenue of $84.6 million and for the full year net revenue...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|